News Headlines Article

Exasperated lawmakers grill drugmakers over high insulin costs
Modern Healthcare

Insulin manufacturers and pharmacy benefit managers in a U.S. House of Representatives hearing Wednesday pointed fingers at one another over patient costs for insulin but ultimately urged lawmakers to keep the rebate system in place.

But the blame game about the system frustrated both Democratic and GOP lawmakers of the House Energy and Commerce Committee oversight panel, who issued sharp warnings of reform. They are focusing on insulin as one part of the broader drug-pricing issue.